Cantor Fitzgerald & Co. Continues Expansion of Healthcare Equity Research Team

NEW YORK, Oct. 10, 2014 /PRNewswire/ -- Cantor Fitzgerald & Co., a leading financial services firm, today announced the expansion of its Healthcare Equity Research team with the appointment of Caroline Corner, Ph.D.,  who will serve as Managing Director, and Daniel Brims, Ph.D., who will serve as Vice President.  Ms. Corner will focus on equity research of medical technology companies and Mr. Brims will focus on biotechnology companies.  They will both report to Christina Valauri, Global Director of Research, and work under Mara Goldstein, who was recently promoted to Head of U.S. Healthcare Research.

"We are very pleased to welcome Caroline and Daniel to Cantor," said Shawn P. Matthews, Chief Executive Officer of Cantor Fitzgerald & Co.  "Both Caroline and Daniel have a deep understanding of healthcare fundamentals and their appointment further underscore our commitment to providing unparalleled market intelligence, insight and service for our clients.  We are excited to further enhance our product offering with recognized leaders in this key sector, and to leverage their depth of knowledge and experience."

Christina Valauri added, "The addition of both Caroline and Daniel to our team further strengthens our presence in the healthcare sector, specifically in the biotechnology and biomedical fields, and compliments our already comprehensive view of the industries and companies we cover."  

Ms. Corner previously served in Investor Relations with Solazyme, Inc.  Earlier, she worked at MLV & Co. as a senior research analyst, and also held senior positions at Pacific Growth Equities and Wells Fargo Securities.   Prior to entering equity research, she held engineering and product development positions at Baxter Transfusion Therapies and Eli Lilly and Company. Ms. Corner received her Ph.D. in Biological Engineering from Cornell University and a B.S. in Biological Systems Engineering from Virginia Tech.

Mr. Brims recently served as a senior research analyst at Brean Capital, LLC, where he covered the biotechnology sector.  Earlier, he worked at Regeneron Pharmaceuticals, where he ran a core facility to support research and development.  Mr. Brims holds a Ph.D. in Chemistry from the University of Washington, B.S. in Chemistry from the University of Wisconsin, and completed a postdoctoral research fellowship at Albert Einstein College of Medicine.

About Cantor Fitzgerald 
Cantor Fitzgerald, a leading global financial services group at the forefront of financial and technological innovation has been a proven and resilient leader for over 65 years. Cantor is a preeminent investment bank serving more than 7,000 institutional clients around the world, recognized for its strengths in fixed income and equity capital markets, investment banking, prime brokerage, and commercial real estate finance and for its global distribution platform. Cantor Fitzgerald & Co. is one of 22 primary dealers authorized to trade U.S. government securities with The Federal Reserve Bank of New York. Cantor Fitzgerald's 1,600 employees serve clients through over 35 locations, including major financial centers around the world in the Americas, Europe, Asia/Pacific, and the Middle East. For more information please visit www.cantor.com.

Note to Editors: Cantor Fitzgerald, L.P., led by Chairman and Chief Executive Officer Howard W. Lutnick, is the parent entity of Cantor Fitzgerald & Co., led by Chief Executive Officer Shawn P. Matthews.

Logo - http://photos.prnewswire.com/prnh/20110721/MM39818LOGO

SOURCE Cantor Fitzgerald & Co.